table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Non-prescription Drugs Market Size Analysis from 2022 to 2027
1.5.1 Global Non-prescription Drugs Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Non-prescription Drugs Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Non-prescription Drugs Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Non-prescription Drugs Industry Impact
Chapter 2 Global Non-prescription Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Non-prescription Drugs (Volume and Value) by Type
2.1.1 Global Non-prescription Drugs Consumption and Market Share by Type (2016-2021)
2.1.2 Global Non-prescription Drugs Revenue and Market Share by Type (2016-2021)
2.2 Global Non-prescription Drugs (Volume and Value) by Application
2.2.1 Global Non-prescription Drugs Consumption and Market Share by Application (2016-2021)
2.2.2 Global Non-prescription Drugs Revenue and Market Share by Application (2016-2021)
2.3 Global Non-prescription Drugs (Volume and Value) by Regions
2.3.1 Global Non-prescription Drugs Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Non-prescription Drugs Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Non-prescription Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Non-prescription Drugs Consumption by Regions (2016-2021)
4.2 North America Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.10 South America Non-prescription Drugs Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Non-prescription Drugs Market Analysis
5.1 North America Non-prescription Drugs Consumption and Value Analysis
5.1.1 North America Non-prescription Drugs Market Under COVID-19
5.2 North America Non-prescription Drugs Consumption Volume by Types
5.3 North America Non-prescription Drugs Consumption Structure by Application
5.4 North America Non-prescription Drugs Consumption by Top Countries
5.4.1 United States Non-prescription Drugs Consumption Volume from 2016 to 2021
5.4.2 Canada Non-prescription Drugs Consumption Volume from 2016 to 2021
5.4.3 Mexico Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 6 East Asia Non-prescription Drugs Market Analysis
6.1 East Asia Non-prescription Drugs Consumption and Value Analysis
6.1.1 East Asia Non-prescription Drugs Market Under COVID-19
6.2 East Asia Non-prescription Drugs Consumption Volume by Types
6.3 East Asia Non-prescription Drugs Consumption Structure by Application
6.4 East Asia Non-prescription Drugs Consumption by Top Countries
6.4.1 China Non-prescription Drugs Consumption Volume from 2016 to 2021
6.4.2 Japan Non-prescription Drugs Consumption Volume from 2016 to 2021
6.4.3 South Korea Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 7 Europe Non-prescription Drugs Market Analysis
7.1 Europe Non-prescription Drugs Consumption and Value Analysis
7.1.1 Europe Non-prescription Drugs Market Under COVID-19
7.2 Europe Non-prescription Drugs Consumption Volume by Types
7.3 Europe Non-prescription Drugs Consumption Structure by Application
7.4 Europe Non-prescription Drugs Consumption by Top Countries
7.4.1 Germany Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.2 UK Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.3 France Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.4 Italy Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.5 Russia Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.6 Spain Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.7 Netherlands Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.8 Switzerland Non-prescription Drugs Consumption Volume from 2016 to 2021
7.4.9 Poland Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 8 South Asia Non-prescription Drugs Market Analysis
8.1 South Asia Non-prescription Drugs Consumption and Value Analysis
8.1.1 South Asia Non-prescription Drugs Market Under COVID-19
8.2 South Asia Non-prescription Drugs Consumption Volume by Types
8.3 South Asia Non-prescription Drugs Consumption Structure by Application
8.4 South Asia Non-prescription Drugs Consumption by Top Countries
8.4.1 India Non-prescription Drugs Consumption Volume from 2016 to 2021
8.4.2 Pakistan Non-prescription Drugs Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Non-prescription Drugs Market Analysis
9.1 Southeast Asia Non-prescription Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Non-prescription Drugs Market Under COVID-19
9.2 Southeast Asia Non-prescription Drugs Consumption Volume by Types
9.3 Southeast Asia Non-prescription Drugs Consumption Structure by Application
9.4 Southeast Asia Non-prescription Drugs Consumption by Top Countries
9.4.1 Indonesia Non-prescription Drugs Consumption Volume from 2016 to 2021
9.4.2 Thailand Non-prescription Drugs Consumption Volume from 2016 to 2021
9.4.3 Singapore Non-prescription Drugs Consumption Volume from 2016 to 2021
9.4.4 Malaysia Non-prescription Drugs Consumption Volume from 2016 to 2021
9.4.5 Philippines Non-prescription Drugs Consumption Volume from 2016 to 2021
9.4.6 Vietnam Non-prescription Drugs Consumption Volume from 2016 to 2021
9.4.7 Myanmar Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 10 Middle East Non-prescription Drugs Market Analysis
10.1 Middle East Non-prescription Drugs Consumption and Value Analysis
10.1.1 Middle East Non-prescription Drugs Market Under COVID-19
10.2 Middle East Non-prescription Drugs Consumption Volume by Types
10.3 Middle East Non-prescription Drugs Consumption Structure by Application
10.4 Middle East Non-prescription Drugs Consumption by Top Countries
10.4.1 Turkey Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.3 Iran Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.5 Israel Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.6 Iraq Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.7 Qatar Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.8 Kuwait Non-prescription Drugs Consumption Volume from 2016 to 2021
10.4.9 Oman Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 11 Africa Non-prescription Drugs Market Analysis
11.1 Africa Non-prescription Drugs Consumption and Value Analysis
11.1.1 Africa Non-prescription Drugs Market Under COVID-19
11.2 Africa Non-prescription Drugs Consumption Volume by Types
11.3 Africa Non-prescription Drugs Consumption Structure by Application
11.4 Africa Non-prescription Drugs Consumption by Top Countries
11.4.1 Nigeria Non-prescription Drugs Consumption Volume from 2016 to 2021
11.4.2 South Africa Non-prescription Drugs Consumption Volume from 2016 to 2021
11.4.3 Egypt Non-prescription Drugs Consumption Volume from 2016 to 2021
11.4.4 Algeria Non-prescription Drugs Consumption Volume from 2016 to 2021
11.4.5 Morocco Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 12 Oceania Non-prescription Drugs Market Analysis
12.1 Oceania Non-prescription Drugs Consumption and Value Analysis
12.2 Oceania Non-prescription Drugs Consumption Volume by Types
12.3 Oceania Non-prescription Drugs Consumption Structure by Application
12.4 Oceania Non-prescription Drugs Consumption by Top Countries
12.4.1 Australia Non-prescription Drugs Consumption Volume from 2016 to 2021
12.4.2 New Zealand Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 13 South America Non-prescription Drugs Market Analysis
13.1 South America Non-prescription Drugs Consumption and Value Analysis
13.1.1 South America Non-prescription Drugs Market Under COVID-19
13.2 South America Non-prescription Drugs Consumption Volume by Types
13.3 South America Non-prescription Drugs Consumption Structure by Application
13.4 South America Non-prescription Drugs Consumption Volume by Major Countries
13.4.1 Brazil Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.2 Argentina Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.3 Columbia Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.4 Chile Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.5 Venezuela Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.6 Peru Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Non-prescription Drugs Consumption Volume from 2016 to 2021
13.4.8 Ecuador Non-prescription Drugs Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Non-prescription Drugs Business
14.1 Pfizer
14.1.1 Pfizer Company Profile
14.1.2 Pfizer Non-prescription Drugs Product Specification
14.1.3 Pfizer Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Roche
14.2.1 Roche Company Profile
14.2.2 Roche Non-prescription Drugs Product Specification
14.2.3 Roche Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Sanofi
14.3.1 Sanofi Company Profile
14.3.2 Sanofi Non-prescription Drugs Product Specification
14.3.3 Sanofi Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Johnson & Johnson
14.4.1 Johnson & Johnson Company Profile
14.4.2 Johnson & Johnson Non-prescription Drugs Product Specification
14.4.3 Johnson & Johnson Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Merck & Co. (MSD)
14.5.1 Merck & Co. (MSD) Company Profile
14.5.2 Merck & Co. (MSD) Non-prescription Drugs Product Specification
14.5.3 Merck & Co. (MSD) Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Novartis
14.6.1 Novartis Company Profile
14.6.2 Novartis Non-prescription Drugs Product Specification
14.6.3 Novartis Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 AbbVie
14.7.1 AbbVie Company Profile
14.7.2 AbbVie Non-prescription Drugs Product Specification
14.7.3 AbbVie Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Gilead Sciences
14.8.1 Gilead Sciences Company Profile
14.8.2 Gilead Sciences Non-prescription Drugs Product Specification
14.8.3 Gilead Sciences Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 GlaxoSmithKline (GSK)
14.9.1 GlaxoSmithKline (GSK) Company Profile
14.9.2 GlaxoSmithKline (GSK) Non-prescription Drugs Product Specification
14.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 Amgen
14.10.1 Amgen Company Profile
14.10.2 Amgen Non-prescription Drugs Product Specification
14.10.3 Amgen Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 AstraZeneca
14.11.1 AstraZeneca Company Profile
14.11.2 AstraZeneca Non-prescription Drugs Product Specification
14.11.3 AstraZeneca Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 Bristol-Myers Squibb
14.12.1 Bristol-Myers Squibb Company Profile
14.12.2 Bristol-Myers Squibb Non-prescription Drugs Product Specification
14.12.3 Bristol-Myers Squibb Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Eli Lilly
14.13.1 Eli Lilly Company Profile
14.13.2 Eli Lilly Non-prescription Drugs Product Specification
14.13.3 Eli Lilly Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.14 Teva
14.14.1 Teva Company Profile
14.14.2 Teva Non-prescription Drugs Product Specification
14.14.3 Teva Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.15 Bayer
14.15.1 Bayer Company Profile
14.15.2 Bayer Non-prescription Drugs Product Specification
14.15.3 Bayer Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.16 Novo Nordisk
14.16.1 Novo Nordisk Company Profile
14.16.2 Novo Nordisk Non-prescription Drugs Product Specification
14.16.3 Novo Nordisk Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.17 Allergan
14.17.1 Allergan Company Profile
14.17.2 Allergan Non-prescription Drugs Product Specification
14.17.3 Allergan Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.18 Shire
14.18.1 Shire Company Profile
14.18.2 Shire Non-prescription Drugs Product Specification
14.18.3 Shire Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.19 Boehringer Ingelheim
14.19.1 Boehringer Ingelheim Company Profile
14.19.2 Boehringer Ingelheim Non-prescription Drugs Product Specification
14.19.3 Boehringer Ingelheim Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.20 Takeda
14.20.1 Takeda Company Profile
14.20.2 Takeda Non-prescription Drugs Product Specification
14.20.3 Takeda Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Non-prescription Drugs Market Forecast (2022-2027)
15.1 Global Non-prescription Drugs Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Non-prescription Drugs Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Non-prescription Drugs Value and Growth Rate Forecast (2022-2027)
15.2 Global Non-prescription Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Non-prescription Drugs Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Non-prescription Drugs Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Non-prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Non-prescription Drugs Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Non-prescription Drugs Consumption Forecast by Type (2022-2027)
15.3.2 Global Non-prescription Drugs Revenue Forecast by Type (2022-2027)
15.3.3 Global Non-prescription Drugs Price Forecast by Type (2022-2027)
15.4 Global Non-prescription Drugs Consumption Volume Forecast by Application (2022-2027)
15.5 Non-prescription Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
